Imunon, Inc. · NASDAQ:IMNN
Imunon — Celsion — Cowen and Company 32nd Annual Health Care Conference 2012
21 slides from Imunon's conference presentation, Mar 7, 2012
Slide 1: Cowen and Company 32nd Annual Health Care Conference
Ut) Celsion Corporation ~~ Cowen and Company 32" Annual Health Care Conference March 5 — 7, 2012 NASDAQ: CLSN Presented by: Michael H. Tardugno President and Chief Executive Officer
Slide 2: Safe Harbor Statement
De Safe Harbor Statement Celsion Corporati Except for historical information, the statements made in this presentation are forward-looking statements involving significant risks and uncertainties. These risks and uncertainties, including those related to the future financial position and business st
Slide 3: Investment Profile
Celsion Investment Profile Celsion Corporation Oncology focused development stage company addressing largest unmet need in cancer - Hepatocellular Carcinoma (HCC) Platform technology provides highly effective, targeted delivery of approved chemotherapeutics ThermoDox® is in a Phase III pivotal trial
Slide 4: Phase III HEAT Study
Phase III HEAT Study Celsion Corporation Special Protocol Assessment for US = 600 patient enrollment target reached; continuing to 700 (r 1:1) 79 Clinical Sitesin 11 Countries = 380 PFS events Primary Endpoint Registration Cohorts in = 372 deaths for Overall Survival (secondary endpoint read out) Gh
Slide 5: Phase III HEAT Study: RFA + ThermoDox for HCC
CMT) | Phase Ill HEAT Study: Celsion RFA + ThermoDox for HCC Primary Endpoint: Progression Free Survival Overall Survival, Time to Local Recurrence, Time to Definite Endpoints: Worsening, and Safety General Eligibility: = Non-resectable HCC = No more than 4 lesions » Atleast 1 lesion > 3cm and none
Slide 6: Fastest Path Regulatory Strategy
2 CRT) Celsion Investment Profile Celsion Fastest Path Regulatory Strategy Corporation So ‘#1 unaddressed Cancer HBV & HCV put millions at risk, globally Eo i<j == NIH “Priority Trial” CDC “growing global healthcare issue” a PTE Tne TemaSSI IE Ss 2 ~=Agreed to SPA Supported by 10 regulatory agencies
Slide 7: Interim Analysis by the DMC Supports Continuation
Celsion Investment Profile Celsion Interim Analysis by the DMC Supports Continuation arpuraiien Unanimous Recommendation to Complete the Study after Interim Efficacy Review by DMC (Nov 2011) In Full Alignment Following Discussions with FDA (Q1-2012) " No additional interim efficacy analyses = Specia
Slide 8: ThermoDox Pre-Clinical Studies
Do TIEIE ThermoDox Pre-Clinical Studies Chemotherapy Directly to Tumor with Superior Activity IN VITRO After 1 hour at 42°C, heat-sensitive formulation delivered most drug to tumor 25 ng/img =43 uM Doxorubicin ThermoDox Amount of Dox bound to DNA, RNA Doxil Amount of Dox still inside liposomes or bo
Slide 9: Hepatocellular Carcinoma (HCC)
A |] Hepatocellular Carcinoma (HCC) Celsion F A Corporation 1st Indication 5th most prevalent cancer globally 4th highest mortality Local therapies include: « Age-adjusted HCC » 5-year survival rate less » RFA, TACE, ethanol incidence rates tripled in than 10% injection, and radiation U.S. between 1
Slide 10: RF Liver Ablation + ThermoDox
I RF Liver Ablation + ThermoDox Celsion Corporation Expanding the Treatment Zone Addresses RFA Limitations RFA misses micro- metastases outside ; ThermoDox ablation zone Ablation Zone ThermoDox + RFA: fe :-——_ Thermal Zone Infuse ThermoDox ; ~15 minutes prior to RFA Drug concentrates in the “Thermal
Slide 11: Phase I Liver Cancer Results
Phase | Liver Cancer Results Celsion Highly Suggestive of Clinical Activity = 2 Clinical Sites: NCI (US) and Queen Mary Hospital (HK) = Single dose treatment; 50mg/m? MTD established = No unanticipated SAE or AE experienced Pre-treatment ee Bland RFA RFA + ThermoDox 11 weeks post-treatment = fr = £
Slide 12: Phase I Liver Cancer Results: Dose Response
QU) MIE Phase | Liver Cancer Results Dose Response Correlation Supports Phase III PFS Endpoint TTP in days |24 Pts Total 9 Pts HCC 20mg 30mg 40mg 50mg = 185 days to progression at the MTD, 50mg/m? a 6 fold improvement over the baseline, 20mg/m?2 (1) = Dose uniquely shows statistical significance, p=
Slide 13: Studied Liver Cancers Revenue Potential
TEE | Studied Liver Cancers Revenue Potential Celsion Corporati Addressable Incidence Growing +5% Annually WW 1600 » 1400 - 1200 1000 800 600 BHCC = MLC “Total Incidence (in 000’s) 2013 2014 2015 2016 2017 2013E 2014E 2015E 2016E 2017E
Slide 14: ThermoDox Clinical Program
J ThermoDox Clinical Program Evaluating Multiple Oncology Indications Corporati PHASES 1-2 PHASE 3 Celsion INDICATION RESEARCH PRE-CLINICAL Pri Li ‘ » Cancer (HCC) HEAT Study Pivotal 5 Enrollment Objective of 600 patients reached cer) 2 RCW Breast & Cancer (RCW) DIGNITY Study Phase II 6 Planning Pha
Slide 15: ThermoDox + Hyperthermia: RCW Breast Cancer
MEME | ThermoDox + Hyperthermia Celsion 2nd Indication: RCW Breast Cancer Corporat my my © 16 patients, 100% show clinical activity SD, PR, CR DIG NITY Stu dy » At 30 mg/m?, 6/6 subjects showed a clinical . RCW study of ThermoDox® + response with 2 Complete Responses and microwave hYperthermia Compl
Slide 16: ThermoDox + RFA: Liver Cancer Metastases
ThermoDox + RFA Celsion Corporati 3rd Indication: Liver Cancer Metastases (The ABLATE Study) Breast Initiated in two sites Lung 1st patient enrolled in Adrenal Q1- 2012 Pancreas Expanding to 4 sites by raion mid year ThermoDox experience in 2 Phase II Study of ThermoDox Phase | studies in Colorectal
Slide 17: ThermoDox Commercialization Strategy
ThermoDox Commercialization Strategy Celsion Corporation Global commercialization plans maximize shareholder value » U.S. strategy is to market and sell directly » Ex-U.S. strategy is through license agreements with Pharma Partner Japan license completed with Yakult Honsha in 2008 $4.5 million Signi
Slide 18: Patent and Regulatory Protection
Celsion Investment Profile Patent and Regulatory Protection = Exclusive world-wide rights from Duke University Patent to 2018+ = Additional U.S Patent extends to 2021 = Orphan Drug Designation in U.S. and Europe provides 7 and 10 year exclusivity Technology platform expandable to a range of therapeu
Slide 19: Balance Sheet Supports Major Operational Goals
Celsion Investment Profile Celsion Corporation Balance Sheet Supports Major Operational Goals Top-line data from Phase III HCC Trial RCW Breast Cancer study Phase II CR Liver Mets study Completion of Commercial Manufacturing Development Experienced Management Team over 27 NDA’s Drug Development Expe
Slide 20: Financial Summary
| Financial Summary As of September 30, 2011 Cash & Investments Recent Financing Activity (Dec 2011) Projected average cash usage per month Common shares outstanding 52-week PPS Range Average Daily Trading Volume Market Capitalization Celsion Corporation $21.4M $15.0 M ~$1.7M 33.2 M $1.69 - $4.37 >
Slide 21: Corporate Information
Celsion’ Corporation ~~ Corporate Information Celsion Corporation 997 Lenox Drive Suite 100 Lawrenceville, NJ 08648 P 609-896-9100 F 609-896-2200 www.celsion.com NASDAQ: CLSN
Celsion — Cowen and Company 32nd Annual Health Care Conference 2012 on 6ix